U.S. Physical Therapy, Inc. Forecast, price target & analysts
U.S. Physical Therapy, Inc. Target price 2025 - Analyst rating & recommendation
U.S. Physical Therapy, Inc. Classifications & Recommendation:
U.S. Physical Therapy, Inc. Price Target
| Target Price | $114.50 |
| Price | $82.42 |
| Potential |
38.92%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target U.S. Physical Therapy, Inc. 2026 .
The average U.S. Physical Therapy, Inc. target price is $114.50.
This is
38.92%
register free of charge
$124.00
50.45%
register free of charge
$108.00
31.04%
register free of charge
|
|
| A rating was issued by 7 analysts: 6 Analysts recommend U.S. Physical Therapy, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the U.S. Physical Therapy, Inc. stock has an average upside potential 2026 of
38.92%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 671.35 | 743.77 |
| 11.00% | 10.79% | |
| EBITDA Margin | 12.56% | 12.37% |
| 10.91% | 1.50% | |
| Net Margin | 4.14% | 5.35% |
| 29.50% | 29.36% |
6 Analysts have issued a sales forecast U.S. Physical Therapy, Inc. 2025 . The average U.S. Physical Therapy, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an U.S. Physical Therapy, Inc. EBITDA forecast 2025. The average U.S. Physical Therapy, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 U.S. Physical Therapy, Inc. Analysts have issued a net profit forecast 2025. The average U.S. Physical Therapy, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.84 | 2.64 |
| 43.75% | 43.48% | |
| P/E | 31.25 | |
| EV/Sales | 2.36 |
3 Analysts have issued a U.S. Physical Therapy, Inc. forecast for earnings per share. The average U.S. Physical Therapy, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the U.S. Physical Therapy, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
U.S. Physical Therapy, Inc....
Current U.S. Physical Therapy, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities | Locked ➜ Locked | Locked | Dec 16 2024 |
| JMP Securities | Locked ➜ Locked | Locked | Dec 16 2024 |
| JP Morgan | Locked ➜ Locked | Locked | Dec 03 2024 |
| Barrington Research | Locked ➜ Locked | Locked | Nov 21 2024 |
| Barrington Research | Locked ➜ Locked | Locked | Nov 07 2024 |
| Barrington Research | Locked ➜ Locked | Locked | Oct 09 2024 |
| B of A Securities | Locked ➜ Locked | Locked | Oct 07 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities: Locked ➜ Locked
|
Dec 16 2024 |
|
Locked
JMP Securities: Locked ➜ Locked
|
Dec 16 2024 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Dec 03 2024 |
|
Locked
Barrington Research: Locked ➜ Locked
|
Nov 21 2024 |
|
Locked
Barrington Research: Locked ➜ Locked
|
Nov 07 2024 |
|
Locked
Barrington Research: Locked ➜ Locked
|
Oct 09 2024 |
|
Locked
B of A Securities: Locked ➜ Locked
|
Oct 07 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
